Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366120 | 0.97 | CHRM2 (0.49) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 | |
| SCHEMBL16506943 | 0.84 | SLC6A3 (0.55) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 | |
| SCHEMBL1769960 | 0.82 | HDAC4 (0.54) | CHRM2CHRM1 | |
| SCHEMBL2023 | 0.82 | OPRM1 (0.48) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 | |
| SCHEMBL2795429 | 0.80 | AKR1C3 (0.58) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 | |
| SCHEMBL3517260 | 0.80 | CHRM2 (0.54) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 | |
| SCHEMBL7369535 | 0.80 | SLC6A4 (0.44) | SLC6A3SLC6A4SLC6A2CCR2 | |
| SCHEMBL16521037 | 0.80 | SLC6A3 (0.45) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 | |
| SCHEMBL7384834 | 0.80 | HDAC4 (0.46) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 | |
| SCHEMBL7895547 | 0.80 | CHRM2 (0.51) | SLC6A3SLC6A4CHRM2CHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057443-A1 | Cycloalkyl Amine Compounds | PREXA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057443-A1 | Cycloalkyl Amine Compounds | PREXA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20150057443-A1 | Cycloalkyl Amine Compounds | PREXA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| WO-2015027058-A2 | CYCLOLKYL AMINE COMPOUNDS | PREXA PHARMACEUTICALS, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20030073681-A1 | 2-substituted piperidines that are ligands for monoamine receptors and transporters | SEPRACOR INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003016274-A2 | 2-SUBSTITUTED PIPERIDINES THAT ARE LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS | SEPRACOR, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0970090-B1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | KNOLL GMBH (DE) | 2002-06-05 | — | — | EP | disclosed |
| US-6187802-B1 | 3-(1-(3,4-DICHLOROPHENYL)CYCLOBUTYL)-5,6-DIHYDROIMIDAZO(2,1-B) THIAZOLE, FOR EXAMPLE; ADMINISTERING TO TREAT DEPRESSION, ANXIETY, PARKINSON'S DISEASE, OBESITY, COGNITIVE DISORDERS, SEIZURES, AND FOR NEUROPROTECTION AGAINST STROKE | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-02-13 | — | — | US | disclosed |
| EP-0970090-A1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Knoll AG (DE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0715620-B1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | KNOLL AG (DE) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998041528-A1 | SUBSTITUTED 4-ARYLMETHYLENE-2-IMINO-2,3-DIHYDROTHIAZOLES AND DERIVATIVES AND THEIR PHARMACEUTICAL USE | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| US-5652271-A | ANTIDEPRESSANTS, NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | disclosed |
| EP-0715620-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | Knoll AG (DE) | 1996-06-12 | — | — | EP | disclosed |
| WO-1994026704-A1 | 1-ARYLCYCLOALKYL SULPHIDES, SULPHOXIDES AND SULPHONES FOR THE TREATMENT OF DEPRESSION, ANXIETY AND PARKINSON'S DISEASE | THE BOOTS COMPANY PLC (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057443-A1 | Cycloalkyl Amine Compounds | HCRTR2, HCRTR1, HTR2C | SLC6A3 108/4885SLC6A4 223/4885CHRM2 10/4885 |
| US-20030073681-A1 | 2-substituted piperidines that are ligands for monoamine receptors and transporters | HTR2C, HTR5A, HTR2A | SLC6A3 10/4885SLC6A4 18/4885CHRM2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.